--- title: "Regen Biopharma (RGBP) news: convertible notes and Nasdaq notice" url: "https://aibio.space/companies/regen-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "RGBP convertible notes, Nasdaq notice and settlement news: Regen Biopharma issues 77,849,847 shares to settle convertible debt. Regen Biopharma, Inc." --- RGBP Regen Biopharma, Inc. OTC · United States # Regen Biopharma (RGBP) news RGBP convertible notes, Nasdaq notice and settlement news Distress · 2026-08-13 ## [Regen Biopharma files late-filing notice for its June 30, 2026 quarterly report](https://aibio.space/news/regen-biopharma-files-late-filing-notice-june-30-2026-quarterly-report/) Regen Biopharma says a delay in its public accountant's review kept it from finishing the Form 10-Q for the period ended June 30, 2026. It says it will file within five calendar days of the due date. ## Latest Regen Biopharma news 1. 2026-03-04 Financings [Regen Biopharma issues 77,849,847 shares to settle convertible debt](https://aibio.space/news/regen-biopharma-issues-77-849-847-shares-settle-convertible-debt/) Regen Biopharma issued 77,849,847 common shares between February 4 and February 27, 2026 to settle convertible debt and fees. The company had 212,318,424 shares outstanding on March 3, 2026, and its pipeline has not yet entered a clinical trial. 2. 2024-12-26 Listings [Regen Biopharma files Form 15 for common and Series A preferred stock](https://aibio.space/news/regen-biopharma-files-form-15-common-series-preferred-stock/) The notice lists 482 holders of record of common stock and 480 of Series A preferred stock. It relies on Rule 12h-3(b)(1)(ii). ## Regen Biopharma at a glance - **Ticker**: RGBP - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $239 ### Related companies - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) NASDAQ: DMAC - [Design Therapeutics](https://aibio.space/companies/design-therapeutics/) NASDAQ: DSGN - [United Therapeutics](https://aibio.space/companies/united-therapeutics/) NASDAQ: UTHR - [Longeveron](https://aibio.space/companies/longeveron/) NASDAQ: LGVN - [Carisma Therapeutics](https://aibio.space/companies/carisma-therapeutics/) OTC: CARM - [Precigen](https://aibio.space/companies/precigen/) NASDAQ: PGEN - [Rocket Pharmaceuticals](https://aibio.space/companies/rocket-pharmaceuticals/) NASDAQ: RCKT - [Halberd](https://aibio.space/companies/halberd/) OTC: HALB ### Also on OTC - [Calithera Biosciences](https://aibio.space/companies/calithera-biosciences/) CALA - [TFA Therapeutics](https://aibio.space/companies/tfa-therapeutics/) RAJAF - [Herborium Group](https://aibio.space/companies/herborium/) HBRM - [Wuhan General Group (China)](https://aibio.space/companies/wuhan-general-china/) WUHN - [Cannabis Bioscience International Holdings](https://aibio.space/companies/cannabis-bioscience-international/) CBIH - [Oncology Pharma](https://aibio.space/companies/oncology-pharma/) ONPH ## What Regen Biopharma does Regen Biopharma, Inc. is a Nevada company that intends to develop regenerative medical applications. It plans to license, develop internally or acquire these applications up to the successful completion of Phase I or Phase II clinical trials, after which it would sell or license them or advance them to Phase III. The company says no clinical trials on its product candidates have commenced. One program, HemaXellarate, is a cellular composition of autologous stromal vascular fraction derived from adipose tissue, which the company believes can regenerate a patient's bone marrow. The company filed an IND with the FDA on February 5, 2013 for a Phase I trial in drug-refractory aplastic anemia, and the FDA later said the clinical hold issues had been addressed. The company has also requested orphan drug designation for HemaXellarate. Other programs include dCellVax, autologous dendritic cells treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase and aimed at breast cancer; tCellVax and DiffronC, which use siRNA against the NR2F6 gene; and DuraCar, CAR-T cells treated with an shRNA targeting NR2F6, which is in pre-clinical testing. The company also holds patents covering NR2F6 modulation and related approaches. | Product or program | What it is | Stage | |---|---|---| | HemaXellarate | Autologous stromal vascular fraction cells for drug-refractory aplastic anemia | Phase I; no clinical trials commenced | | dCellVax | Autologous dendritic cells treated with an IDO siRNA inhibitor, aimed at breast cancer | no clinical trials commenced | | tCellVax | Patient immune cells treated with siRNA to inhibit NR2F6 | no clinical trials commenced | | DiffronC | In vivo siRNA targeting NR2F6 to inhibit cancer growth and activate T cells | no clinical trials commenced | | DuraCar | CAR-T cells treated with an shRNA targeting NR2F6 | pre-clinical testing | Summarised from the company's [10-K filed Dec 30, 2025](https://www.sec.gov/Archives/edgar/data/1589150/000149315225029526/form10-k.htm). ## Regen Biopharma annual financials | Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 | |---|---|---| | Research and development | [$11,725](https://www.sec.gov/Archives/edgar/data/1589150/000149315225029526/) | [$153,685](https://www.sec.gov/Archives/edgar/data/1589150/000149315225029526/) | | Net income (loss) | [-$1.3 million](https://www.sec.gov/Archives/edgar/data/1589150/000149315225029526/) | [-$668,255](https://www.sec.gov/Archives/edgar/data/1589150/000149315225029526/) | | Cash from operations | [-$383,591](https://www.sec.gov/Archives/edgar/data/1589150/000149315225029526/) | [-$751,536](https://www.sec.gov/Archives/edgar/data/1589150/000149315225029526/) | | Cash and equivalents | [$69,555](https://www.sec.gov/Archives/edgar/data/1589150/000149315226038576/) | [$716](https://www.sec.gov/Archives/edgar/data/1589150/000149315225029526/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $239. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Regen Biopharma Has Regen Biopharma sold convertible notes? Our latest story on this, dated Mar 4, 2026: "Regen Biopharma issues 77,849,847 shares to settle convertible debt". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/regen-biopharma-issues-77-849-847-shares-settle-convertible-debt/). Has Regen Biopharma received a Nasdaq deficiency notice? Our latest story on this, dated Aug 13, 2026: "Regen Biopharma files late-filing notice for its June 30, 2026 quarterly report". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/regen-biopharma-files-late-filing-notice-june-30-2026-quarterly-report/). Has Regen Biopharma settled a lawsuit? Our latest story on this, dated Mar 4, 2026: "Regen Biopharma issues 77,849,847 shares to settle convertible debt". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/regen-biopharma-issues-77-849-847-shares-settle-convertible-debt/). What is the ticker symbol of Regen Biopharma? Regen Biopharma, Inc. trades under the ticker RGBP on OTC. Where is Regen Biopharma listed? Regen Biopharma, Inc. is listed on OTC. Our directory also records these other listings: OTC:RGBPP. What is the SEC CIK of Regen Biopharma? The SEC Central Index Key (CIK) for Regen Biopharma, Inc. is 1589150. Its filings are on SEC EDGAR. How many shares does Regen Biopharma have outstanding? 1,675,277,503 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-17. Which country or territory is Regen Biopharma listed under? Our directory records Regen Biopharma, Inc. under United States. What does Regen Biopharma do? Our directory classifies Regen Biopharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Regen Biopharma? The ISIN recorded for Regen Biopharma, Inc. is US75886M3007. Does aibio.space cover Regen Biopharma? aibio.space lists Regen Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Regen Biopharma incorporated? SEC records list its state or country of incorporation as NV. What does Regen Biopharma develop? Regen Biopharma, Inc. is a Nevada company that intends to develop regenerative medical applications. It plans to license, develop internally or acquire these applications up to the successful completion of Phase I or Phase II clinical trials, after which it would sell or license them or advance them to Phase III. What is HemaXellarate from Regen Biopharma? HemaXellarate: Autologous stromal vascular fraction cells for drug-refractory aplastic anemia Stage: Phase I; no clinical trials commenced. What is dCellVax from Regen Biopharma? dCellVax: Autologous dendritic cells treated with an IDO siRNA inhibitor, aimed at breast cancer Stage: no clinical trials commenced. ## Investor discussion: Regen Biopharma Members talk about Regen Biopharma (RGBP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Regen Biopharma, newest first. Each line links the filing it comes from. 1. 2026-08-13 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1589150/000149315226037682/formnt10-q.htm) 2. 2026-07-15 Legal Reported a change of independent auditor. SEC Form 8-K (Items 1.01,4.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1589150/000149315226033364/form8-k.htm) 3. 2026-03-04 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). [Source](https://www.sec.gov/Archives/edgar/data/1589150/000149315226008837/form8-k.htm) 4. 2026-02-02 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). [Source](https://www.sec.gov/Archives/edgar/data/1589150/000149315226004733/form8-k.htm) 5. 2025-12-30 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1589150/000149315225029526/form10-k.htm) 6. 2025-11-13 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). [Source](https://www.sec.gov/Archives/edgar/data/1589150/000149315225022185/form8-k.htm) 7. 2025-10-03 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1589150/000149315225016767/form8-k.htm) 8. 2025-09-19 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). [Source](https://www.sec.gov/Archives/edgar/data/1589150/000149315225014182/form8-k.htm) 9. 2025-06-11 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1589150/000164117225014652/form8-k.htm) 10. 2025-05-13 Legal Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). [Source](https://www.sec.gov/Archives/edgar/data/1589150/000164117225009967/form8-k.htm) 11. 2025-05-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1589150/000164117225009968/form10-k.htm) 12. 2025-04-07 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01). [Source](https://www.sec.gov/Archives/edgar/data/1589150/000164117225002908/form8-k.htm) 13. 2024-12-26 Listings Filed to end its SEC reporting. SEC Form 15-15D. [Source](https://www.sec.gov/Archives/edgar/data/1589150/000149315224052071/form15-15d.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:RGBP on TradingView](https://www.tradingview.com/symbols/OTC-RGBP/). ## SEC filings and registration - **SEC name**: Regen BioPharma Inc - **CIK**: 1589150 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: RGBP (OTC), RGBPP (OTC) - **State or country of incorporation**: NV - **Fiscal year ends**: September 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 4700 SPRING ST #304, LA MESA, CA, 91942 - **Phone**: 619-722-5505 - **Shares outstanding**: 1,675,277,503 as of 2026-08-12 (10-Q filed 2026-08-17) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1589150/000149315226038576/form10-q.htm) filed 2026-08-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1589150/000149315226033364/form8-k.htm) filed 2026-07-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1589150/000149315226022924/form10-q.htm) filed 2026-05-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1589150/000149315226008837/form8-k.htm) filed 2026-03-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1589150/000149315226006526/form10-q.htm) filed 2026-02-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1589150/000149315226004733/form8-k.htm) filed 2026-02-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1589150/000149315226002956/form8-k.htm) filed 2026-01-21 - [10-K](https://www.sec.gov/Archives/edgar/data/1589150/000149315225029526/form10-k.htm) filed 2025-12-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001589150), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Regen Biopharma, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker RGBP, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Regen Biopharma, Inc. - **Ticker**: RGBP - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US75886M3007 - **Other listed symbols**: OTC:RGBPP - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-RGBP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/regen-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Regen Biopharma (RGBP) news: convertible notes and Nasdaq notice", 2026-10-31, https://aibio.space/companies/regen-biopharma/